MenopauseNCT06336564
Microablative Radiofrequency in the Treatment of Urinary Symptoms Associated With Genitourinary Syndrome of Menopause
A study testing Pelvic floor muscle training and Microablative Radiofrequency in people with Menopause and Urinary Incontinence, run by Centro de Atenção ao Assoalho Pélvico at 1 site in Brazil.
Trial summary
Genitourinary Syndrome fo Menopause (GSM) is made up of a set of changes in the region of the vulva, vagina and lower urinary tract associated with a decrease in estrogen levels in the urogenital tissue, which leads to a reduction in blood supply, disorders in collagen metabolism and skin elasticity. Read more about this study
- Who is it for?
- Ages 40 to 65 years, women only
- Conditions the study is for
- Menopause, Urinary Incontinence
- What is being tested?
- Pelvic floor muscle training and Microablative Radiofrequency
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteBrazil
- Study dates
- Aug 2025to Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Clinical complaint of urinary incontinence associated to Genitourinary Syndrome of Menopause.
- Negative cervical oncotic cytology, within the last 3 years.
Who cannot join
- Patients with cognitive deficit;
- Patients with chronic degenerative neurological diseases;
- Post-void residue greater than 50 ml;
- Carriers of a pacemaker and implantable cardioverter defibrillator;
- Use of hormonal therapy (topical or systemic) starting in the 2 months prior to the initial assessment;
- Patients undergoing brachytherapy or pelvic radiotherapy;
- Patients that had reconstructive pelvic surgery;
- Pregnant women.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Brazil1 site
Centro de Atenção ao Assoalho Pelvico
Salvador, Estado de Bahia, 40.290-000
About this study
Official title: Microablative Radiofrequency in the Treatment of Urinary Symptoms Associated With Genitourinary Syndrome of Menopause: Randomized Clinical Trial
Genitourinary Syndrome fo Menopause (GSM) is made up of a set of changes in the region of the vulva, vagina and lower urinary tract associated with a decrease in estrogen levels in the urogenital tissue, which leads to a reduction in blood supply, disorders in collagen metabolism and skin elasticity. The standard treatment for urinary incontinence during menopause is pelvic floor muscle training, associated or not with local hormone replacement therapy. Although low cost and easy to access, it is associated with low patient's adherence. Physical methods such as laser and radiofrequency in non-ablative, ablative and microablative forms are technologies that have recently been used in the vaginal mucosa to promote neoelastogenesis and neocollagenesis. It is hypothesized that menopausal women, who present symptoms of GSM, may benefit from this new, minimally invasive resource (microablative radiofrequency). This is a randomized clinical trial in which women aged between 40 and 65 years old will be included with clinical complaints of urinary symptoms associated with GSM. A basic anamnestic questionnaire will be used as the study instrument to collect sociodemographic, clinical data and symptoms, following the routine and standard of the service. To evaluate the treatment, the following will be used: voiding diary, pad test, vaginal cytology, histopathology, Female Sexual Function Index (FSFI), Short-Form Health Survey - SF-36 Questionnaire, King's Health Questionnaire, evolution of symptoms (dryness, pain during sexual activity, vaginal laxity, itching, burning sensation and pain in the vaginal introitus) and level of patient's satisfaction. Patients will be randomized into: group 1 or control group, which will perform pelvic floor muscle training, PFMT, with supervision (three times) and at home twice a day, and group 2 or test group, which will perform the same PFMT protocol associated with vaginal microablative radiofrequency. 10% lidocaine spray will be applied three minutes before the procedure and three applications will be made to the vagina/vaginal introitus, with an interval of 30 to 40 days. The purpose of this study is to test the efficacy and duration of effect of microablative radiofrequency in the treatment of urinary symptoms associated with GSM.
- Conditions
- Menopause, Urinary Incontinence
- Being tested
- Pelvic floor muscle training, Microablative Radiofrequency
- Keywords
- Genitourinary syndrome of menopause, Microablative Radiofrequency
- Medical subject headings
- Urinary Incontinence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Pelvic floor muscle trainingOther
Verbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform "The Knack", which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days.
Microablative RadiofrequencyDevice
Patients will be placed in the lithotomy position and through speculum examination and under direct vision or guided by colposcope, sequential application of radiofrequency will be carried out on the vaginal walls and introitus. The Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic energy fractionation circuit, connected to a vaginal pen with 64 microneedles, 200μm in diameter and 1 mm in length, mounted on a Teflon body and divided into a matrix of eight columns with eight needles each. In the vestibule and vaginal opening, 10% lidocaine spray will be applied three minutes before the procedure. Three applications will be carried out in the vagina/vaginal introitus, with an interval of 30 to 40 days.
| Study group | Role | What they receive |
|---|---|---|
| Control Group | Active comparator | Pelvic floor muscle training Receives: Other: Pelvic floor muscle training |
| Intervention Group | Experimental | Pelvic floor muscle training and microablative radiofrequency Receives: Other: Pelvic floor muscle training; Device: Microablative Radiofrequency |
What is being measured
The primary outcome is the main question the study is designed to answer.
Resolution or improvement of episodes of urinary loss assessed by pad test
Participants will perform the one-hour Pad Test to diagnose and quantify urinary loss. Initially, the absorbent will be placed in a closed plastic bag and weighed on a precision electronic scale (Denver Instrument®). Then, the participant will be instructed to put on the pad, drink 500 ml of water in a maximum of 15 minutes and remain at rest for another 15 minutes, this phase represents 30 minutes of the test. In the other 30 minutes, the participant will be asked to perform certain standardized activities simulating activities of daily life (going up and down stairs, sitting down and standing up ten times, coughing ten times, picking up objects from the floor five times, running in the same place for one minute and washing the hands under running water for one minute).
Measured: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
Resolution or improvement of episodes of urinary loss assessed by urinary diary
Participants will be instructed to keep a voiding diary at home for three days to record water intake, urinary volume and the number of incontinence episodes, as well as episodes of urgency and nocturnal enuresis.
Measured: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Number of patients with tolerability related to treatment assessed by Likert Scale.
Likert scale of 3 points will be asked to the patients: 1) impossible to tolerate the treatment, 2) not nice, but possible to tolerate, 3) very tolerable.
Measured: At each of the three sessions (every 30 to 40 days), 30 days after the end of treatment and 12 months after the end of the treatment.
Number of patients with adverse effects related to treatment assessed by histopathology.
To evaluate the safety in tissue effect of FRAXX, samples of vaginal tissue will be obtained through a biopsy taken from the lateral walls, in the middle third of the vagina, for histopathological study. Procedure carried out under colposcopic vision, using a 3mm loop attached to the radiofrequency device, "surgery" mode, removing a small vaginal fragment.
Measured: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
Resolution or improvement of episodes of urinary loss assessed by questionnaire.
The questionnaire to be used will be International Consultation on Incontinence Questionnaire- Short Form (ICIQ-SF) which is a self-administered questionnaire that assesses the impact of UI on quality of life and the classification of urinary loss. The ICIQ-SF is composed of four questions that assess the frequency, severity and impact of UI, in addition to a set of eight self-diagnosis items, related to the causes or situations of UI experienced by patients. The higher the score, the greater the severity of urinary incontinence and the greater the impact on the patient's quality of life.
Measured: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
Secondary outcomes (7)
Recovery of vaginal health assessed by Vaginal Index Maturation
The cytological evaluation will be carried out using a vaginal smear collected from the lateral vaginal wall with a spatula ; the percentage of superficial (%S), intermediate (%I) and parabasal (P%) cells are counted and the mucosa is then classified according to the Vaginal Maturation Index (VMI) of the Meisel formula [(1, 0 x %S) + (0.5 x %I) + (0.0 x %P)] as atrophic, hypotrophic or eutrophic.
Measured: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Recovery of vaginal health assessed by vaginal pH
Vaginal pH will be measured with a pH indicator strip between 0 and 14 (MColorpHastTM, Merck, Germany), placed in contact with the mucosa of the middle third of the vaginal canal, with the help of a speculum.
Measured: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Improvement of Sexual Function assessed by Female Sexual Function Index
A self-administered questionnaire, which proposes to evaluate female sexual response in the domains: sexual desire, sexual arousal, vaginal lubrication, orgasm, sexual satisfaction and pain. It presents 19 questions that assess sexual function in the last four weeks and presents scores for each component. For each question there is a response pattern, between 0 and 5 in an increasing order, except for questions about pain, where the score is reversed. The domain that presents a score equal to zero means that the interviewee did not report sexual intercourse in the last four weeks. Individual scores are obtained by summing the items that comprise each domain (simple score), which are multiplied by the factor of that domain and provide the weighted score. The final score (total score: minimum of 2 and maximum of 36) is obtained by adding the weighted scores for each domain. The cut-off is: > or = 26 points - no sexual dysfunction; bellow 26 - sexual dysfunction.
Measured: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Improvement of quality of life assessed by Short-Form Health Survey (SF-36)
It consists of 36 items that encompass 8 domains: functional capacity, physical aspects, pain, general health, vitality, social aspects, emotional aspects and mental health. It presents a final score from 0 to 100, where zero represents the worst general health status and 100 the best general health status.
Measured: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Improvement or resolution of urinary incontinence and the impact on quality of life assessed by King's Health Questionnaire.
It consists of 21 questions and has four to five answer options on the LIKERT scale. It involves nine domains: general health perceptions, impact of incontinence, function restrictions, physical limitations, social limitations, personal relationships, emotions, sleep and energy, and severity measures. Furthermore, it has an independent scale called Symptom Severity Scale, which contains 11 items, measuring the presence and severity of urinary symptoms. The score, both per domain and its global score, is obtained from a minimum of 0 (best quality of life) to a maximum of 100 (worst quality of life).
Measured: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Degree of patient satisfaction using a five-point Likert scale.
It will classify patient's level of satisfaction as: 1) very dissatisfied; 2) dissatisfied; 3) unchanged; 4) satisfied; 5) very satisfied.
Measured: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Evolution of vaginal symptoms assessed by Visual Analogue Scale (VAS)
Intensity of vaginal symptoms (dryness, pain during sexual activity, vaginal laxity, itching, burning sensation and pain in the vaginal introitus) will be asked to the participants. VAS is divided from 0 to 10 points. 0 will be considered as absence of the symptom and 10 will represent the maximum possible symptom.
Measured: Immediately after the initial physical examination and at the end of each of the three session (every 30 to 40 days).
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Mar 2024
- Study startAug 2025 (estimated)
- Primary completionAug 2026 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MenopauseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized clinical trial
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centro de Atenção ao Assoalho Pélvico
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Patricia Lordelo, Centro de Atenção ao Assoalho Pélvico
- Investigators
- Patrícia Lordelo, PhD, Principal investigator, Pelvic Floor Care Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06336564
- Sponsor's protocol ID
- 71168623.6.0000.5544
- Status last verified
- Aug 2024
- First submitted
- 22 Mar 2024
- Last updated
- 20 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Microablative Radiofrequency in the Treatment of Urinary Symptoms Associated With Genitourinary Syndrome of Menopause: Randomized Clinical Trial
- ClinicalTrials.gov ID
- NCT06336564
- Acronym / sponsor ID
- 71168623.6.0000.5544
- Conditions
- Menopause, Urinary Incontinence
- Keywords
- Genitourinary syndrome of menopause, Microablative Radiofrequency
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Centro de Atenção ao Assoalho PélvicoUniversity, hospital or other
- Study start
- Aug 2025 (estimated)
- Primary completion
- Aug 2026 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 28 Mar 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Genitourinary Syndrome fo Menopause (GSM) is made up of a set of changes in the region of the vulva, vagina and lower urinary tract associated with a decrease in estrogen levels in the urogenital tissue, which leads to a reduction in blood supply, disorders in collagen metabolism and skin elasticity. The standard treatment for urinary incontinence during menopause is pelvic floor muscle training, associated or not with local hormone replacement therapy. Although low cost and easy to access, it is associated with low patient's adherence. Physical methods such as laser and radiofrequency in non-ablative, ablative and microablative forms are technologies that have recently been used in the vaginal mucosa to promote neoelastogenesis and neocollagenesis. It is hypothesized that menopausal women, who present symptoms of GSM, may benefit from this new, minimally invasive resource (microablative radiofrequency). This is a randomized clinical trial in which women aged between 40 and 65 years old will be included with clinical complaints of urinary symptoms associated with GSM. A basic anamnestic questionnaire will be used as the study instrument to collect sociodemographic, clinical data and symptoms, following the routine and standard of the service. To evaluate the treatment, the following will be used: voiding diary, pad test, vaginal cytology, histopathology, Female Sexual Function Index (FSFI), Short-Form Health Survey - SF-36 Questionnaire, King's Health Questionnaire, evolution of symptoms (dryness, pain during sexual activity, vaginal laxity, itching, burning sensation and pain in the vaginal introitus) and level of patient's satisfaction. Patients will be randomized into: group 1 or control group, which will perform pelvic floor muscle training, PFMT, with supervision (three times) and at home twice a day, and group 2 or test group, which will perform the same PFMT protocol associated with vaginal microablative radiofrequency. 10% lidocaine spray will be applied three minutes before the procedure and three applications will be made to the vagina/vaginal introitus, with an interval of 30 to 40 days. The purpose of this study is to test the efficacy and duration of effect of microablative radiofrequency in the treatment of urinary symptoms associated with GSM.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Randomized clinical trial
| Arm | Type | Receives |
|---|---|---|
| Control Group | Active comparator | Other: Pelvic floor muscle trainingPelvic floor muscle training |
| Intervention Group | Experimental | Other: Pelvic floor muscle training, Device: Microablative RadiofrequencyPelvic floor muscle training and microablative radiofrequency |
Who may qualify
- Ages
- 40 to 65 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Clinical complaint of urinary incontinence associated to Genitourinary Syndrome of Menopause.
- Negative cervical oncotic cytology, within the last 3 years.
Key exclusion criteria (8 listed)
- Patients with cognitive deficit;
- Patients with chronic degenerative neurological diseases;
- Post-void residue greater than 50 ml;
- Carriers of a pacemaker and implantable cardioverter defibrillator;
- Use of hormonal therapy (topical or systemic) starting in the 2 months prior to the initial assessment;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pelvic floor muscle trainingVerbal information will be given about location, function and the correct way to contract the pelvic floor muscles (PFM). Participants will be instructed on how to perform "The Knack", which is a pre-contraction of the PFM during some abdominal effort, such as coughing, sneezing or laughing. The exercises consist of two series of 10 maximum contractions sustained for 5 seconds and 10 seconds of relaxation and two series of 10 maximum rapid contractions with two seconds of maintenance and four seconds of relaxation, with one minute of rest between each series. Participants will be instructed to perform the same exercises at home (twice a day) and to fill out a training diary, allowing researchers to monitor and check whether the exercises are actually being performed. The protocol will be repeated with the researcher three times in total, every 30 to 40 days. | Other | Control Group, Intervention Group |
| Microablative RadiofrequencyPatients will be placed in the lithotomy position and through speculum examination and under direct vision or guided by colposcope, sequential application of radiofrequency will be carried out on the vaginal walls and introitus. The Wavetronic 6000 Touch device will be used with the Megapulse HF FRAXX system (Loktal Medical Electronics, São Paulo, Brazil), equipped with an electronic energy fractionation circuit, connected to a vaginal pen with 64 microneedles, 200μm in diameter and 1 mm in length, mounted on a Teflon body and divided into a matrix of eight columns with eight needles each. In the vestibule and vaginal opening, 10% lidocaine spray will be applied three minutes before the procedure. Three applications will be carried out in the vagina/vaginal introitus, with an interval of 30 to 40 days. | Device | Intervention Group |
Primary outcome
Resolution or improvement of episodes of urinary loss assessed by pad test
Time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
Participants will perform the one-hour Pad Test to diagnose and quantify urinary loss. Initially, the absorbent will be placed in a closed plastic bag and weighed on a precision electronic scale (Denver Instrument®). Then, the participant will be instructed to put on the pad, drink 500 ml of water in a maximum of 15 minutes and remain at rest for another 15 minutes, this phase represents 30 minutes of the test. In the other 30 minutes, the participant will be asked to perform certain standardized activities simulating activities of daily life (going up and down stairs, sitting down and standing up ten times, coughing ten times, picking up objects from the floor five times, running in the same place for one minute and washing the hands under running water for one minute).
Resolution or improvement of episodes of urinary loss assessed by urinary diary
Time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Participants will be instructed to keep a voiding diary at home for three days to record water intake, urinary volume and the number of incontinence episodes, as well as episodes of urgency and nocturnal enuresis.
Number of patients with tolerability related to treatment assessed by Likert Scale.
Time frame: At each of the three sessions (every 30 to 40 days), 30 days after the end of treatment and 12 months after the end of the treatment.
Likert scale of 3 points will be asked to the patients: 1) impossible to tolerate the treatment, 2) not nice, but possible to tolerate, 3) very tolerable.
Number of patients with adverse effects related to treatment assessed by histopathology.
Time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
To evaluate the safety in tissue effect of FRAXX, samples of vaginal tissue will be obtained through a biopsy taken from the lateral walls, in the middle third of the vagina, for histopathological study. Procedure carried out under colposcopic vision, using a 3mm loop attached to the radiofrequency device, "surgery" mode, removing a small vaginal fragment.
Resolution or improvement of episodes of urinary loss assessed by questionnaire.
Time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.
The questionnaire to be used will be International Consultation on Incontinence Questionnaire- Short Form (ICIQ-SF) which is a self-administered questionnaire that assesses the impact of UI on quality of life and the classification of urinary loss. The ICIQ-SF is composed of four questions that assess the frequency, severity and impact of UI, in addition to a set of eight self-diagnosis items, related to the causes or situations of UI experienced by patients. The higher the score, the greater the severity of urinary incontinence and the greater the impact on the patient's quality of life.
7 secondary outcomes
Recovery of vaginal health assessed by Vaginal Index Maturation
Time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Recovery of vaginal health assessed by vaginal pH
Time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Improvement of Sexual Function assessed by Female Sexual Function Index
Time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Improvement of quality of life assessed by Short-Form Health Survey (SF-36)
Time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Improvement or resolution of urinary incontinence and the impact on quality of life assessed by King's Health Questionnaire.
Time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Degree of patient satisfaction using a five-point Likert scale.
Time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment
Evolution of vaginal symptoms assessed by Visual Analogue Scale (VAS)
Time frame: Immediately after the initial physical examination and at the end of each of the three session (every 30 to 40 days).
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Aug 2024.
- Individual participant dataSharing planned: No
Related trials for Menopause
Recruiting
Hop Extract Versus Soy Isoflavone Extract for Menopausal Symptoms (HOPES)
Menopause, Perimenopause
Not yet recruiting
The Role of Diet Quality in Sleep Among Women in Postmenopause
Post Menopausal Women
Active, not recruitingPhase 3
Human Menopausal Gonadotropin Research in Infertility Assessing Cumulative Live Birth With Frozen Embryo Transfer.
Infertility (IVF Patients)
Not yet recruiting
Effect of Hormone Replacement Therapy on Physiotherapy Outcomes in Postmenopausal Women With Frozen Shoulder
Frozen Shoulder, Adhesive Capsulitis
RecruitingObservational study
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Patrícia Lordelo, PhD principal investigator
Pelvic Floor Care Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Pelvic floor muscle training and Microablative Radiofrequency in people with Menopause and Urinary Incontinence, run by Centro de Atenção ao Assoalho Pélvico at 1 site in Brazil.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Patricia V Lordelo, PhD (+5571996592400, pvslordelo@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Resolution or improvement of episodes of urinary loss assessed by pad test (time frame: Before the beginning of the treatment, 30 days after the end of treatment and 12 months after the end of the treatment.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2024.